Publication Author: Basu_Anirban

• Predicting utility ratings for joint health States from single health States in prostate cancer: empirical testing of 3 alternative theories.

  Dale W, Basu A, Elstein A, Meltzer D. Predicting utility ratings for joint health States from single health States in prostate cancer: empirical testing of 3 alternative theories. Med Decis Making. 2008 Jan-Feb;28(1):102-12. Epub 2007 Dec 5.

  rakerr2

  January 1, 2008

• Use of instrumental variables in the presence of heterogeneity and self-selection: an application to treatments of breast cancer patients.

  Basu A, Heckman JJ, Navarro-Lozano S, Urzua S. Use of instrumental variables in the presence of heterogeneity and self-selection: an application to treatments of breast cancer patients. Health Econ. 2007 Nov;16(11):1133-57.

  rakerr2

  November 1, 2007

• The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003.

  Huang ES, Basu A, Finch M, Frytak J, Manning W. The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003. Curr Med Res Opin. 2007 Jun;23(6):1423-30. Epub 2007 May 14.

  rakerr2

  June 1, 2007

• Value of information on preference heterogeneity and individualized care.

  Basu A, Meltzer D. Value of information on preference heterogeneity and individualized care. Med Decis Making. 2007 Mar-Apr;27(2):112-27.

  rakerr2

  March 1, 2007

• Scale of interest versus scale of estimation: comparing alternative estimators for the incremental costs of a comorbidity.

  Basu A, Arondekar BV, Rathouz PJ. Scale of interest versus scale of estimation: comparing alternative estimators for the incremental costs of a comorbidity. Health Econ. 2006 Oct;15(10):1091-107.

  rakerr2

  October 1, 2006

• Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach.

  Basu A, Meltzer HY, Dukic V. Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach. Stat Med. 2006 Sep 15;25(17):2886-910.

  rakerr2

  September 15, 2006

• Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era.

  Basu A, Meltzer HY. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophr Res. 2006 Sep;86(1-3):99-109. Epub 2006 Jun 6.

  rakerr2

  September 1, 2006

• Cost-effectiveness of olanzapine as a first-line treatment: a comment.

  Basu A. Cost-effectiveness of olanzapine as a first-line treatment: a comment. Value Health. 2006 Sep-Oct;9(5):357; author reply 358.

  rakerr2

  September 1, 2006

• Health literacy as a predictor of follow-up after an abnormal Pap smear: a prospective study.

  Lindau ST, Basu A, Leitsch SA. Health literacy as a predictor of follow-up after an abnormal Pap smear: a prospective study. J Gen Intern Med. 2006 Aug;21(8):829-34.

  rakerr2

  August 1, 2006

• Implications of spillover effects within the family for medical cost-effectiveness analysis.

  Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ. 2005 Jul;24(4):751-73. Epub 2005 Apr 22.

  rakerr2

  July 1, 2005